

EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND BETA-  
ADRENERGIC ANTAGONIST COMBINATION THERAPY FOR  
TREATMENT OF CONGESTIVE HEART FAILURE

5

ABSTRACT

09917403.072701

A combination therapy comprising a therapeutically-effective amount of an epoxy-steroidal aldosterone receptor antagonist and a therapeutically-effective amount of a beta-adrenergic antagonist is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites.

10 Preferred beta-adrenergic antagonists are those compounds having high potency and bioavailability. Preferred epoxy-steroidal aldosterone receptor antagonists are 20-spiroxane steroidal compounds characterized by the presence of a  $9\alpha,11\alpha$ -substituted epoxy moiety. A preferred combination therapy includes

15 the beta-adrenergic antagonist metoprolol (( $\pm$ )) 1-(isopropylamino)-3-[p-(2-methoxyethyl)phenoxy]-2-propanolol succinate) and the aldosterone receptor antagonist epoxymexrenone.

20